Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$66 Mln
Revenue (TTM)
$30 Mln
Net Profit (TTM)
$-71 Mln
ROE
-1.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.6
Face value
--
Shares outstanding
60,824,500
CFO
$-136.27 Mln
EBITDA
$-197.77 Mln
Net Profit
$-207.86 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Surface Oncology (SURF)
| 30.5 | 11.5 | 39.0 | -21.9 | -45.5 | -36.4 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
Surface Oncology (SURF)
| -82.8 | -48.3 | 391.5 | -55.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
1.1 | 65.7 | 30.0 | -94.0 | -286.4 | -137 | -- | 0.5 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal... antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc. Read more
Pres, CEO & Director
Dr. Robert W. Ross M.D.
Pres, CEO & Director
Dr. Robert W. Ross M.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Surface Oncology Inc (SURF) is $1.07 (NASDAQ) as of 12-Sep-2023 09:30 EDT. Surface Oncology Inc (SURF) has given a return of -45.47% in the last 3 years.
Since, TTM earnings of Surface Oncology Inc (SURF) is negative, P/E ratio is not available.
The P/B ratio of Surface Oncology Inc (SURF) is 0.47 times as on 12-Sep-2023, a 88 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.76
|
0.53
|
|
2021
|
-2.79
|
1.87
|
|
2020
|
6.74
|
2.57
|
|
2019
|
-0.99
|
0.93
|
|
2018
|
-17.79
|
1.14
|
The 52-week high and low of Surface Oncology Inc (SURF) are Rs -- and Rs -- as of 03-Apr-2026.
Surface Oncology Inc (SURF) has a market capitalisation of $ 66 Mln as on 12-Sep-2023. As per SEBI classification, it is a company.
Before investing in Surface Oncology Inc (SURF), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.